Adam J Paulsen1, Carla R Schubert1, Alex Pinto1, Cynthia M Carlsson2,3, Richard J Chappell4,5, Mary E Fischer1, Barbara E K Klein1, Ronald Klein1, Michael Y Tsai6, Karen J Cruickshanks1,7. 1. Departments of Ophthalmology and Visual Sciences. 2. Medicine. 3. Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI. 4. Biostatistics and Medical Informatics. 5. Department of Statistics, University of Wisconsin. 6. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN. 7. Population Health Sciences, University of Wisconsin, School of Medicine and Public Health.
Abstract
BACKGROUND: Relationships between brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), aldosterone, and cognition in aging were evaluated in the population-based Epidemiology of Hearing Loss Study (1993 to present). METHODS: Beginning in 1998 to 2000, cognitive impairment was assessed by report of physician diagnoses and the Mini-Mental State Examination. In 2009 to 2010 and 2013 to 2016, information was collected on diagnosis of mild cognitive impairment/dementia. Decline in cognitive function was assessed by principal component analysis from additional tests administered during 2009 to 2010 and 2013 to 2016. BDNF, IGF-1, and aldosterone were measured in serum collected in 1998 to 2000. RESULTS: There were 1970 participants (mean age=66.9 y; 59.1% female) without cognitive impairment at baseline. Among women, low BDNF was associated with 16-year incident cognitive impairment [hazard ratio=1.76; 95% confidence interval (CI)=1.04, 2.98]. Among men, increasing IGF-1 was associated with decreased risk [per SD: relative risk (RR)=0.57; 95% CI=0.35, 0.92], whereas increasing aldosterone levels were associated with increased risk (per SD: RR=1.28; 95% CI=1.01, 1.62) for 5-year incident mild cognitive impairment/dementia. Overall, low BDNF was associated with increased risk (RR=1.52; 95% CI=1.02, 2.26) for 5-year cognitive decline. CONCLUSION: Low levels of serum BDNF and IGF-1 were associated with poorer cognition during aging. There may be differential biomarker effects by sex.
BACKGROUND: Relationships between brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), aldosterone, and cognition in aging were evaluated in the population-based Epidemiology of Hearing Loss Study (1993 to present). METHODS: Beginning in 1998 to 2000, cognitive impairment was assessed by report of physician diagnoses and the Mini-Mental State Examination. In 2009 to 2010 and 2013 to 2016, information was collected on diagnosis of mild cognitive impairment/dementia. Decline in cognitive function was assessed by principal component analysis from additional tests administered during 2009 to 2010 and 2013 to 2016. BDNF, IGF-1, and aldosterone were measured in serum collected in 1998 to 2000. RESULTS: There were 1970 participants (mean age=66.9 y; 59.1% female) without cognitive impairment at baseline. Among women, low BDNF was associated with 16-year incident cognitive impairment [hazard ratio=1.76; 95% confidence interval (CI)=1.04, 2.98]. Among men, increasing IGF-1 was associated with decreased risk [per SD: relative risk (RR)=0.57; 95% CI=0.35, 0.92], whereas increasing aldosterone levels were associated with increased risk (per SD: RR=1.28; 95% CI=1.01, 1.62) for 5-year incident mild cognitive impairment/dementia. Overall, low BDNF was associated with increased risk (RR=1.52; 95% CI=1.02, 2.26) for 5-year cognitive decline. CONCLUSION: Low levels of serum BDNF and IGF-1 were associated with poorer cognition during aging. There may be differential biomarker effects by sex.
Authors: Alexandra M V Wennberg; Clinton E Hagen; Mary M Machulda; John H Hollman; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Michelle M Mielke Journal: Neurobiol Aging Date: 2018-02-19 Impact factor: 4.673
Authors: Per Johansson; Daniel Åberg; Jan-Ove Johansson; Niklas Mattsson; Oskar Hansson; Bo Ahrén; Jörgen Isgaard; N David Åberg; Kaj Blennow; Henrik Zetterberg; Anders Wallin; Johan Svensson Journal: Psychoneuroendocrinology Date: 2013-03-06 Impact factor: 4.905
Authors: Pirjo Komulainen; Maria Pedersen; Tuomo Hänninen; Helle Bruunsgaard; Timo A Lakka; Miia Kivipelto; Maija Hassinen; Tuomas H Rauramaa; Bente K Pedersen; Rainer Rauramaa Journal: Neurobiol Learn Mem Date: 2008-09-06 Impact factor: 2.877
Authors: Carmilla M M Licht; Lise C van Turenhout; Jan Berend Deijen; Lando L J Koppes; Willem van Mechelen; Jos W R Twisk; Madeleine L Drent Journal: Int J Endocrinol Date: 2014-07-10 Impact factor: 3.257
Authors: Raquel Herrero-Labrador; Angel Trueba-Saiz; Laura Martinez-Rachadell; Mᵃ Estrella Fernandez de Sevilla; Jonathan A Zegarra-Valdivia; Jaime Pignatelli; Sonia Diaz-Pacheco; Ana M Fernandez; Ignacio Torres Aleman Journal: Int J Mol Sci Date: 2020-12-18 Impact factor: 5.923
Authors: Vanessa B Serrano; Jessica L Montoya; Laura M Campbell; Erin E Sundermann; Jennifer Iudicello; Scott Letendre; Robert K Heaton; David J Moore Journal: J Neurovirol Date: 2021-11-04 Impact factor: 2.643